Welcome to our dedicated page for Alterity Therapeutics American Depositary Shares news (Ticker: ATHE), a resource for investors and traders seeking the latest updates and insights on Alterity Therapeutics American Depositary Shares stock.
Alterity Therapeutics Limited (symbol: ATHE) is a pioneering biopharmaceutical company based in Melbourne, Australia, focused on developing therapeutic drugs for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and multiple system atrophy. Founded in 1997 and originally known as Prana Biotechnology Limited, the company rebranded to Alterity Therapeutics Limited in April 2019.
The company’s flagship drug candidate, ATH434, has successfully completed Phase I clinical trials and is geared towards treating Parkinson's disease and other associated movement disorders. The drug has shown promise in clinical evaluations to slow disease progression, thus improving the quality of life for patients.
Alterity is also advancing PBT2, another leading drug candidate, originally designed as an antimicrobial agent but repurposed for treating Alzheimer's and Huntington's diseases. PBT2 has garnered attention owing to its potential to tackle the cognitive decline associated with these debilitating conditions.
Alterity Therapeutics is actively engaged in multiple research collaborations and partnerships with academic institutions and pharmaceutical companies to enhance its drug development pipeline. Their multi-faceted approach to addressing neurodegenerative disorders underscores the company's commitment to innovation and patient care.
Recent achievements include a collaborative study titled “A multimodal approach for diagnosis of early Multiple System Atrophy,” presented at the MDS 2023 conference, demonstrating the company's dedication to advancing scientific understanding and treatment methodologies.
Financially, Alterity Therapeutics maintains a stable condition, actively investing in research and development to push forward its clinical programs. The company's strategic initiatives and ongoing projects highlight its pivotal role in the healthcare domain, with a focus on creating significant therapeutic advancements.
For investors and stakeholders, Alterity Therapeutics represents a compelling opportunity in the biopharmaceutical sector, with a clear focus on addressing unmet medical needs through innovative drug discovery and development.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced findings from the bioMUSE study at the American Academy of Neurology Annual Meeting, showcasing wearable sensors' effectiveness in quantifying motor impairment in patients with Multiple System Atrophy (MSA). The analysis involved 17 participants and indicated a strong correlation between sensor parameters and traditional clinical assessments of motor impairment. This data is significant for future clinical trials, as wearable sensors will be integrated as secondary endpoints in the ongoing Phase 2 trial of ATH434. ATH434 aims to address neurodegeneration and has shown promise in preclinical studies. The ongoing research is pivotal for understanding MSA's progression and optimizing treatment methods.
Alterity Therapeutics (ATHE) has initiated its Phase 2 clinical trial for ATH434 in the UK, targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. This trial is a randomized, double-blind, placebo-controlled study intended to evaluate ATH434's effects on neuroimaging and protein biomarkers. With the first UK participant dosed, the trial aims to enroll approximately 60 adults over 12 months, focusing on efficacy and safety. ATH434 has shown preclinical promise and is acknowledged with Orphan designation by the U.S. FDA and European Commission for MSA treatment, indicating significant therapeutic potential for this debilitating condition.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the dosing of the first participant in its Phase 2 clinical trial of ATH434 for Multiple System Atrophy (MSA) on March 16, 2023. This pivotal trial is being conducted at Vanderbilt University Medical Center and will involve approximately 60 adults. The study is designed to evaluate the effect of ATH434 on neuroimaging and biomarkers specific to MSA pathology, along with safety and efficacy measures. ATH434 aims to inhibit pathological protein aggregation and has shown promise in preclinical studies. The trial is critical for developing a potential treatment option for the 15,000 individuals living with MSA in the U.S.
Alterity Therapeutics (NASDAQ: ATHE) announced the granting of a key patent by the USPTO for over 100 novel compounds targeting neurodegenerative diseases, including Alzheimer’s. This patent provides 20 years of exclusivity for these compounds with an acyl hydrazone (AH) structure. Additionally, Alterity has entered a licensing agreement with Professor Colin Masters to further evaluate its patented compounds and its legacy asset, PBT2, in Alzheimer’s treatment. PBT2 has demonstrated efficacy in clinical trials and is currently the Company’s primary candidate for Alzheimer’s disease.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) announced the dosing of its first participant in Italy for a Phase 2 clinical trial of ATH434, targeting Multiple System Atrophy (MSA), a rare neurodegenerative disorder. This randomized, double-blind, placebo-controlled trial will assess ATH434's impact on neuroimaging, protein biomarkers, and clinical efficacy. The study, set to enroll 60 adults over 12 months, aims to optimize the design for a future Phase 3 study. ATH434 has demonstrated preclinical success in reducing α-synuclein pathology and has Orphan designation from the U.S. FDA and European Commission.
FAQ
What is the current stock price of Alterity Therapeutics American Depositary Shares (ATHE)?
What is the market cap of Alterity Therapeutics American Depositary Shares (ATHE)?
What does Alterity Therapeutics Limited specialize in?
What are the company's lead drug candidates?
Where is Alterity Therapeutics Limited based?
What was Alterity Therapeutics formerly known as?
What recent achievements has the company made?
Who is the CEO of Alterity Therapeutics Limited?
What is the financial condition of Alterity Therapeutics?
What does ATH434 target?
What does PBT2 target?
What type of collaborations is Alterity Therapeutics engaged in?
